Radionuclide Drug Conjugates (RDCs)

Providing integrated pre-clinical services, hit finding, conjugate preparation,
in vitro/in vivo evaluation in oncology and immuno-oncology.

Therapeutic Modalities

Integrated pre-clinical RDC services

Radionuclide Drug Conjugates (RDCs) unite radionuclides, chelators, linkers, and targeting molecules, allowing radiation to be delivered directly to tumor cells. This targeted mechanism leverages direct DNA damage to overcome conventional drug resistance while enabling simultaneous therapeutic evaluation and precise tumor imaging. WuXi Biology offers an integrated preclinical RDC platform, featuring diverse ligand screening, complex conjugate preparation, and cutting-edge molecular imaging to accelerate your discovery.

RDCs Discovery

Ligand discovery and RDC synthesis

In vitro evaluation

In vivo evaluation

Ligand discovery and RDC synthesis

Hit finding platforms for targeting moiety discovery in RDCs

Learn more about in vitro screening platform

Tracking Records

• 15+ years of experience

• 1800+ clients

• 1000+ target screened

• 2200+ proteins produced

• Screen successful rate >90%

• Validated hit from DEL directly entered the Phase III clinical trials

• Strongest hit (KD = 312 pM) identified via DEL

RDC conjugation services

Chelators

Wide range of chelators, including DFO, DTPA, and custom options (Figure 1)

3-week average turnaround for chelator synthesis, including complex ones like DFO (＞95% purity)

Radiochemical labelling and quantitative

Expertise in both hot and cold metal chelation

Advanced methods for radiolabeling and synthesis of radiopharmaceutical compounds

Access to over 20 different radionuclides for diverse applications

iTLC, Radio-HPLC for QC

Gamma Counter for radioactivity quantitative measurement

Raw data archiving on NAS 480T

License issued RDCs

¹⁸F, ¹¹C, ⁶⁸Ga, ⁶⁴Cu, ⁸⁹Zr, ¹²³I, ¹³N, ¹³¹I, ¹⁷⁷Lu, ⁹⁰Y, ¹²⁴I, ³²P, ^99mTc, ²²⁷Th, ²²⁵Ac, ²²³Ra, ²⁰³Pb, ²¹²Pb, ²¹¹At, ²¹³Bi.

In Vitro evaluation of RDC

Learn more about in vitro biology services

Our capabilities

Membrane Target Assay Capabilities

Target binding affinity

Cellular internalization and localization

Target kinetics: competition, on/off rate

Target-Related Studies

Functional markers of receptor signaling events

Apoptosis / Necrosis / DNA damage assessment

Generic biochemical / cellular assays

Cost-Effective Assay Options for RDC

³H / ¹⁴C / ¹²⁵I based high-throughput screening

Cold-labeled time-resolved fluorescence assay

In Vitro Pharmacology

In Vitro Pharmacology

Short-term killing assessment (metabolic activity)

Long-term proliferation inhibition (colony formation, 3D culture spheroid system)

Radiation sensitization / drug resistance evaluation

Human iPSC-induced organoid assay systems for in vitro toxicity evaluation (for salivary gland / Proximal renal tubule, and more…)

Customized Assays Upon Requests….

With extensive experiences on 100+ membrane targets of multiple classes, our team is prepared for emerging first-in-class RDC targets from our clients

In Vitro binding and internalization assay of ¹⁷⁷Lu-RDC

Binding and internalization of ¹⁷⁷Lu-RDC to prostate cancer cells with different PSMA expression level. Cells were incubated with ¹⁷⁷-Lu-RDC for certain time courses at designated concentrations (Figure 3); specific binding, internalization and kinetic trends of ¹⁷⁷Lu-RDC were determined after washing (Figure 4).